Last updated: 15 June 2019 at 8:57am EST

Marc Unger Net Worth




The estimated Net Worth of Marc Unger is at least $26.1 Mille dollars as of 22 August 2016. Marc Unger owns over 1,663 units of Standard BioTools Inc stock worth over $26,118 and over the last 9 years Marc sold FLDM stock worth over $0.

Marc Unger FLDM stock SEC Form 4 insiders trading

Marc has made over 1 trades of the Standard BioTools Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Marc exercised 1,663 units of FLDM stock worth $6,170 on 22 August 2016.

The largest trade Marc's ever made was exercising 1,663 units of Standard BioTools Inc stock on 22 August 2016 worth over $6,170. On average, Marc trades about 208 units every 0 days since 2015. As of 22 August 2016 Marc still owns at least 7,040 units of Standard BioTools Inc stock.

You can see the complete history of Marc Unger stock trades at the bottom of the page.



What's Marc Unger's mailing address?

Marc's mailing address filed with the SEC is FLUIDIGM CORPORATION, 7000 SHORELINE COURT, SUITE 100, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Standard BioTools Inc

Over the last 14 years, insiders at Standard BioTools Inc have traded over $29,087,682 worth of Standard BioTools Inc stock and bought 4,143,303 units worth $24,269,186 . The most active insiders traders include Easterly Partners Llcle Par..., Capital Strategies, L.P.Lev... e Samuel D Colella. On average, Standard BioTools Inc executives and independent directors trade stock every 9 days with the average trade being worth of $72,208. The most recent stock trade was executed by Nicolas Barthelemy on 1 April 2022, trading 20,993 units of FLDM stock currently worth $78,514.



What does Standard BioTools Inc do?

Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Its customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, the Company strives to increase the quality of life for all.



Complete history of Marc Unger stock trades at Standard BioTools Inc

Persona
Trans.
Transazione
Prezzo totale
Marc Unger
See Remarks
Opzione $15,632
22 Aug 2016


Standard BioTools Inc executives and stock owners

Standard BioTools Inc executives and other stock owners filed with the SEC include: